Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 1, 2008, Pages 61-67

  Davies, Yinka K ^a   Cox, Kathleen M ^a   Abdullah, Bisher A ^b   Safta, Anca ^d   Terry, Annie B ^c   Cox, Kenneth L ^a  

^a STANFORD UNIVERSITY   (United States)

^b Mary Bridge Children's Hospital   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Autoantibodies; Colitis; Fibrosis; Inflammatory bowel disease; Primary sclerosing cholangitis; Tumor necrosis factor; Vancomycin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; SALAZOSULFAPYRIDINE; VANCOMYCIN; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; COUGHING; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LONG TERM CARE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; PRESCHOOL CHILD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; DISEASE COURSE; ENZYMOLOGY; LIVER; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PROSPECTIVE STUDY; SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; BLOOD SEDIMENTATION; CHILD; CHILD, PRESCHOOL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 55549136784     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31816fee95     Document Type: Article

References (27)

1. El-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987;92:1226- 35.
2. Roberts EA. Primary sclerosing cholangitis in children. J Gastroenterol Hepatol 1999;14:588-93.
3. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002;51:562-6.
4. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
5. Narayanan Menon KV,Wiesner RH. Etiology and natural history of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg 1999;6:343-51.
6. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32.
7. Dienes HP, Lohse AW, Gerken G, et al. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 1997;431:119-24.
8. Kozaiwa K, Tajiri H, Sawada A, et al. Three pediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J Gastroenterol Hepatol 1998;13:825-9.
9. Lindor KD. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study GroupUrsodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
10. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108:1199- 203.
11. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9:727-32.
12. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:580-3.
13. Siedlar M, Szczepanik A, Wieckiewicz J, et al. Vancomycin downregulates lipopolysaccharide-induced tumour necrosis factor a (TNF a) production and TNF a-mRNA accumulation in human blood monocytes. Immunopharmacology 1997;35:265-71.
14. Olsson R, Bjornsson E, Backman L, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998;28:426-32.
15. Bjornsson ES, Kilander AF, Olsson RG. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis- a study of bile cultures from ERCP. Hepatogastroenterology 2000;47:1504-8.
16. Bentur L, Lachter J, Koren I, et al. Severe pulmonary disease in association with Crohn's disease in a 13-year-old girl. Pediatr Pulmonol 2000;29:151-4.
17. Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000;15:41-8.
18. Gohlke F, Lohse AW, Dienes HP, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699-705.
19. Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997; 26:554-9.
20. Cambridge G, Rampton DS, Stevens TR, et al. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992;33:668-74.
21. Chapman RW, Cottone M, Selby WS, et al. Serum autoantibodies, ulcerative colitis, and primary sclerosing cholangitis. Gut 1986; 27:86-91.
22. Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000; 32:182-7.
23. Claise C, Johanet C, Bouhnik Y, et al. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 1996;16:28-34.
24. Van Milligen de Wit AW, van Deventer SJ, Tytgat GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995;90:893-900.
25. Schattner A, Kozak N, Lassry Y, et al. Primary intestinal T-cell lymphoma and sclerosing cholangitis: a cytokine-mediated association? J Intern Med 1998;244:537-41.
26. Bernal W, Moloney M, Underhill J, et al. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol 1999;30:237-41.
27. Bo X, Broome U, Remberger M, et al. Tumour necrosis factor a impairs functionof liver derivedTlymphocytes and natural killer cells in patientswith primary sclerosing cholangitis.Gut 2001;49:131-41.